Acasti Pharma Inc. (ACST)
ACST Price and Sentiment
ACST Latest news
Laval, Quebec--(Newsfile Corp. - November 11, 2021) - Acasti Pharma Inc. (NASDAQ: ACST) (TSXV: ACST) ("Acasti" or the "Company"), today announced that management will present at the Q4 Investor Summit, hosted by the Investor Summit Group, being held virtually on November 16-17, 2021. Jan D'Alvise, President and Chief Executive Officer of Acasti Pharma, is scheduled to present as follows:Event: Q4 Investor SummitDate and Time: Tuesday, November 16 at 3:30 pm Eastern TimeWebcast: https://us06web.zoom.us/webinar/register/WN_Wf9K_2n0QoO3WVYfML50_gA replay of the...
Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2021 Results - Earning Call Transcript
Call to be held on Wednesday, November 10th at 1:00 PM Eastern Time Call to be held on Wednesday, November 10th at 1:00 PM Eastern Time
Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in Japan2021-10-06 08:30
Patents strengthen Acasti's IP portfolio and provide protection through 2036 and 2037, respectively Patents strengthen Acasti's IP portfolio and provide protection through 2036 and 2037, respectively
Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company's Lead Drug Candidate for the Treatment of Subarachnoid Hemorrhage2021-09-27 08:30
Study expected to be completed in the first half of 2022, with the goal to commence the Phase 3 safety study in the second half of 2022 Study expected to be completed in the first half of 2022, with the goal to commence the Phase 3 safety study in the second half of 2022
Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing Standards2021-09-22 08:30
LAVAL, Québec, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today provided a business update and announced that the Nasdaq Stock Market (“Nasdaq”) has confirmed to Acasti that the Company has regained compliance with Nasdaq's minimum bid price requirement.
LAVAL, Québec, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that it will be presenting at the Oppenheimer Fall Healthcare Summit being held virtually September 20-23, 2021.
The clinical-stage pharmaceutical company completed its merger with Grace Therapeutics last week.
Acasti Pharma Announces Successful Completion of its Merger with Grace Therapeutics, Inc., Voting Results of its Annual and Special Meeting of Shareholders and Reverse Stock Split2021-08-27 08:40
LAVAL, Québec, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti”) (NASDAQ: ACST–TSX-V: ACST), announced today the completion of its previously disclosed acquisition of Grace Therapeutics, Inc. (“Grace”) via merger. The successful completion of the merger positions Acasti to build a premier, late-stage specialty pharma company focused on rare diseases. Based on management's current forecasts, Acasti expects to have enough cash on its balance sheet following the merger to provide at least two years of operating runway. The combined companies will be led by Jan D'Alvise as President and Chief Executive Officer, under the oversight of Acasti's newly elected Board of Directors, comprised of four re-elected directors of Acasti and two Grace nominees newly elected as directors (with a third Grace nominee expected to be nominated prior to the next annual meeting of shareholders). All Grace employees will transition to Acasti and they will continue to maintain a research and development laboratory and com
Making a penny stocks watchlist in August? Check these 3 small-caps out The post Are These Penny Stocks on Your Watchlist Right Now?